This video shows a bladder cancer surgery procedure (Transurethral Resection of Bladder Tumor (TURBT) performed with Blue Light as adjunct to White Light Cystoscopy. With courtesy of Maximillian Burger, Germany
Oslo, Norway, 7 August 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 41% in local currency for the U.S. market in the second quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 52.1 million (Q2 2018: NOK 42.4) and a recurring EBITDA of NOK -2.6 million (NOK 0.7 million). The company continues to receive strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and reiterates the significant revenue growth and profit opportunities in the U.S. market.
Oslo, Norway, August 1, 2019 - Photocure ASA (OSE: PHO) management is conducting investor meetings in New York (US) on August 1, 2019, in connection with the European Biotech Investor Day, organized by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients